MA30867B1 - Composes heteroaromatiques bicycliques - Google Patents

Composes heteroaromatiques bicycliques

Info

Publication number
MA30867B1
MA30867B1 MA31844A MA31844A MA30867B1 MA 30867 B1 MA30867 B1 MA 30867B1 MA 31844 A MA31844 A MA 31844A MA 31844 A MA31844 A MA 31844A MA 30867 B1 MA30867 B1 MA 30867B1
Authority
MA
Morocco
Prior art keywords
alkyl
alcoxy
halo
aryl
group
Prior art date
Application number
MA31844A
Other languages
English (en)
Inventor
Colin Andrew Leach
Original Assignee
Glaxo Group Ltd Soc Britannique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd Soc Britannique filed Critical Glaxo Group Ltd Soc Britannique
Publication of MA30867B1 publication Critical patent/MA30867B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION CONCERNE UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE (I) DANS LAQUELLE: R1 REPRÉSENTE UN GROUPE ARYLE, SUBSTITUÉ OU NON SUBSTITUÉ PAR 1, 2, 3 OU 4 SUBSTITUANTS QUI PEUVENT ÊTRE IDENTIQUES OU DIFFÉRENTS, SÉLECTIONNÉS DANS LE GROUPE COMPRENANT: ALKYLE C1-C6, ALCOXY C1-C6, ALKYLTHIO C1-C6, ARYL ALCOXY C1-C6, HYDROXY, HALO, CN, COR6, COOR6, NR6COR7, CONR8R9, SO2NR8R9, NR6SO2R7, NR8R9, HALO C1-C4 ALKYLE ET HALO C1-C4 ALCOXY; W REPRÉSENTE CH ET X REPRÉSENTE N, OU W REPRÉSENTE N ET X REPRÉSENTE CH, OU W ET X REPRÉSENTENT CH; Y REPRÉSENTE C2-C4ALKYLE, R2 REPRÉSENTE HYDROGÈNE, ALKYLE C1-C6, ALCOXY C1-C6, ALKYLTHIO C1-C6, ARYL C1-C6 ALCOXY, HYDROXY, HALO, CN, COR6, CARBOXY, COOR6, NR6COR7, CONR8R9, SO2NR8R9, NR6SO2R7, NR8R9, MONO À PERFLUORO-ALKYLE C1-C6, OU MONO À PERFLUORO-ALCOXY C1-C6; N VAUT ENTRE 0 ET 5; R3 REPRÉSENTE ALKYLE C1-C4; R4 REPRÉSENTE ALKYLE C1-C4; R5 REPRÉSENTE HYDROGÈNE, ALKYLE C1-C10, ALCÉNYLE C2-C10, ALCYNYLE C2-C10, HALO ALKYLE C1-C4, CYCLOALKYLE C3-C8, CYCLOALKYLE C3-C8 ALKYLE C1-C4, CYCLOALCÉNYLE C5-C8, CYCLOALCÉNYL C5-C8 ALKYLE C1-C4, HÉTÉROCYCLOALKYLE À 3 À 8 CHAÎNONS ALKYLE C3-C8 , HÉTÉROCYCLOALKYLE À 3 À 8 CHAÎNONS ALKYLE C1-C4, ARYLE C6-C14, ARYLE C6-C14 ALKYLE C1-C10, HÉTÉROARYLE, OU HÉTÉROARYLE ALKYLE C1_C10; CHAQUE GROUPE ÉTANT ÉVENTUELLEMENT UNE OU PLUSIEURS FOIS SUBSTITUÉ PAR LE MÊME GROUPE ET/OU UN GROUPE DIFFÉRENT QUI EST ALCOXY C1-C6, ALKYLTHIO C1-C6, ARYL C1-C6 ALCOXY, HYDROXY, HALO, CN, NR8R9, OU HALO C1-C4 ALCOXY, R6 ET R7 REPRÉSENTANT INDÉPENDAMMENT HYDROGÈNE OU ALKYLE C1_C10; R8 ET R9 ÉTANT IDENTIQUES OU DIFFÉRENTS ET REPRÉSENTANT HYDROGÈNE OU ALKYLE C1_C10, OU R9 ET R10 ASSOCIÉS À L'AZOTE AUQUEL ILS SONT LIÉS FORMENT UN NOYAU COMPORTANT DE 5 À 7 CHAÎNONS CONTENANT ÉVENTUELLEMENT UN OU PLUSIEURS AUTRES HÉTÉROATOMES SÉLECTIONNÉS PARMI HYDROGÈNE, AZOTE ET SOUFRE, ET ÉVENTUELLEMENT SUBSTITUÉS PAR UN OU DEUX SUBSTITUANTS SÉLECTIONNÉS DANS LE GROUPE COMPRENANT HYDROXY, HALO, OXO, ALKYLE C1-C4, ALKYLCARBOXY C1-C4, ARYLE ET ARYL ALKYLE C1-C4; OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CEUX-CI. LESDITS COMPOSÉS SONT UTILES POUR LE TRAITEMENT DE L'ATHÉROSCLÉROSE OU D'AUTRES MALADIES INFLAMMATOIRES.
MA31844A 2006-10-13 2009-05-06 Composes heteroaromatiques bicycliques MA30867B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82932806P 2006-10-13 2006-10-13
US11/626,882 US7705005B2 (en) 2006-10-13 2007-01-25 Bicyclic heteroaromatic compounds

Publications (1)

Publication Number Publication Date
MA30867B1 true MA30867B1 (fr) 2009-11-02

Family

ID=39303784

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31844A MA30867B1 (fr) 2006-10-13 2009-05-06 Composes heteroaromatiques bicycliques

Country Status (15)

Country Link
US (1) US7705005B2 (fr)
EP (1) EP2081915A4 (fr)
JP (1) JP2010506851A (fr)
KR (1) KR20090079227A (fr)
AU (1) AU2007312995A1 (fr)
BR (1) BRPI0719861A2 (fr)
CA (1) CA2672926A1 (fr)
CO (1) CO6180449A2 (fr)
CR (1) CR10729A (fr)
EA (1) EA200970379A1 (fr)
IL (1) IL197960A0 (fr)
MA (1) MA30867B1 (fr)
MX (1) MX2009003882A (fr)
NO (1) NO20091451L (fr)
WO (1) WO2008048866A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101861883B1 (ko) 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
ES2847883T3 (es) 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
EP2736908A1 (fr) 2011-07-27 2014-06-04 Glaxo Group Limited Composés pyrimidones bicycliques
EP2739627A4 (fr) 2011-07-27 2015-01-21 Glaxo Group Ltd Composés 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one et utilisation en tant qu'inhibiteurs de lp-pla2
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
UY35276A (es) 2013-01-25 2014-08-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos que inhiben la actividad de Lp-PLA2
CA2899124A1 (fr) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Composes
BR112015017397A2 (pt) 2013-01-25 2017-07-11 Glaxosmithkline Ip Dev Ltd compostos pirimidona bicíclica como inibidores de lp-pla2
WO2016012917A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012916A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
CN114805389B (zh) 2019-11-09 2023-08-29 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
TWI896037B (zh) 2023-07-17 2025-09-01 大陸商上海樞境生物科技有限公司 雙環[5,6]咪唑嘧啶酮類衍生物、其製備方法和應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520752A (en) * 2000-02-16 2004-03-26 Smithkline Beecham P Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024807D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024808D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
KR100939651B1 (ko) * 2001-12-07 2010-02-03 소시에떼 드 테크놀로지 미쉐린 부타디엔/이소프렌 공중합체의 제조방법
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds

Also Published As

Publication number Publication date
AU2007312995A1 (en) 2008-04-24
CR10729A (es) 2009-05-25
WO2008048866A3 (fr) 2008-12-24
NO20091451L (no) 2009-07-02
JP2010506851A (ja) 2010-03-04
CO6180449A2 (es) 2010-07-19
EA200970379A1 (ru) 2009-08-28
CA2672926A1 (fr) 2008-04-24
EP2081915A4 (fr) 2011-11-16
WO2008048866A2 (fr) 2008-04-24
BRPI0719861A2 (pt) 2014-06-03
IL197960A0 (en) 2009-12-24
US20080090853A1 (en) 2008-04-17
KR20090079227A (ko) 2009-07-21
EP2081915A2 (fr) 2009-07-29
US7705005B2 (en) 2010-04-27
MX2009003882A (es) 2009-04-22

Similar Documents

Publication Publication Date Title
MA30867B1 (fr) Composes heteroaromatiques bicycliques
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
MA29250B1 (fr) Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a
MA32089B1 (fr) Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
RU2016118768A (ru) Композиции, пригодные для лечения расстройств, связанных с kit
MA32088B1 (fr) Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique
MA28024A1 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
MA26991A1 (fr) Triazolopyridines servant d'agents anti-inflammatoires
MA28271A1 (fr) Dérivés de benzènesulfonylamino-pyridine -2-yle et composés apparentés servant d'inhibiteurs de la 11-bêta- hydroxystéroïde-déshydrogénase de type 1(11-bêta-HSD-1)pour le traitement du diabète et de l'obésité
CA2574600A1 (fr) Derives de pyridine
MA30695B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole -2-carboxamides, leur preparation et leur application en therapeutique.
MA37358B1 (fr) Composition de lutte antiparasitaire comprenant un nouveau dérivé d'iminopyridine
MA26996A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle, servant d'inhibiteurs de nep pour un trouble d'eveil sexuel feminin
MA27247A1 (fr) Utilisation combinee de derive indolopyrrolocarbazole antitumoral et autre agent antitumoral
MA38935B1 (fr) Dérivés de diazacarbazole à titre de ligands tau-pet
MA32642B1 (fr) Amides utiles en therapie
MX369974B (es) Compuestos farmaceuticos.
MA38275B1 (fr) Hétérocycles azotés saturés et n-acylés potentialisant l'activité d'un antibiotique actif contre les mycobactéries
TW200612920A (en) Novel imidazolidine derivatives
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
MY195881A (en) Griseofulvin Compound
MA31629B1 (fr) Dérivés de 1-0x0-1,2-dihydroisoquinoleine-5-carboxamides et de 4-oxo-3,4-dihydroquinazoline-8-carboxamides, leur préparation et leur application en thérapeutique
TNSN05224A1 (fr) Derives azabicycliques a substituants pyridyloxymethyle et benzisoxazole
MA38114A1 (fr) Nouveaux modulateurs androgéniques sélectifs
MA28093A1 (fr) Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine